阿立哌唑与氯氮平治疗首发精神分裂症对照研究

目的评价阿立哌唑治疗精神分裂症的临床疗效及安全性。方法将62例首发精神分裂症患者随机分为两组，各31例，研究组口服阿立哌唑治疗，对照组口服氯氮平治疗，疗程8周。于治疗前及治疗第2、4、8周末采用阳性与阴性症状量表评定临床疗效，副反应量表评定不良反应。结果治疗8周末，研究组总有效率为86．1％，对照组为90。3％，两组比较差异无统计学意义（P〉0．05）。阳性与阴性症状量表评分两组治疗第2周末起总分与因子均较治疗前有极显著性下降（P〈0．01）；两组间周期评分比较轻微，组研究组总不良反应发生率显著低于对照组（P〈0．05）。结论阿立哌唑治疗首发精神分裂症疗效显著，与氯氮平相比，不良反应轻微，安全性更高。

A control study of aripiprazole and clozapine in the treatment of first-episode schizophenia

Objective To evaluate the clinical efficacy and satety of aripiprazole in the treatment of schizophrenia.Methods 62 first-episode[1]schizo-phrenics went randomly divided into research group(n=31)took orally aripiprazole and control group(n=31)did clozapine for 8 weeks.Clinical efficacies were assessed with the Positive and Negative syndrome Scale(PANSS)and adverss effects with the Treatrnent emergent Symptom Scale[TESS] before treatment Emergent and at the end of the 2nd,4th and 8th week treatment.Results At the end of the 8th week,total effective rate was 86.1%in the research and 90.3%in the control group respectively,which showed no signifioant difference(P>0.05).since the end of the 2nd week,the total score and all facors'scores of PANSS lowered very significantly for both groups compared with pretreatment(P<0.01);There was no signifivant difference in synchronization score between the 2 groups(P>0.05).Adverse effects of both groups were milder,but total adverse effects significantly lower in the research than in the control group(P<0.05).Conclusion Aripiprazole has similar efficacy to clozapine,milder side effects,higher safety.